Literature DB >> 17237795

Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.

Kevin C O'Connor1, Katherine A McLaughlin, Philip L De Jager, Tanuja Chitnis, Estelle Bettelli, Chenqi Xu, William H Robinson, Sunil V Cherry, Amit Bar-Or, Brenda Banwell, Hikoaki Fukaura, Toshiyuki Fukazawa, Silvia Tenembaum, Susan J Wong, Norma P Tavakoli, Zhannat Idrissova, Vissia Viglietta, Kevin Rostasy, Daniela Pohl, Russell C Dale, Mark Freedman, Lawrence Steinman, Guy J Buckle, Vijay K Kuchroo, David A Hafler, Kai W Wucherpfennig.   

Abstract

The role of autoantibodies in the pathogenesis of multiple sclerosis (MS) and other demyelinating diseases is controversial, in part because widely used western blotting and ELISA methods either do not permit the detection of conformation-sensitive antibodies or do not distinguish them from conformation-independent antibodies. We developed a sensitive assay based on self-assembling radiolabeled tetramers that allows discrimination of antibodies against folded or denatured myelin oligodendrocyte glycoprotein (MOG) by selective unfolding of the antigen domain. The tetramer radioimmunoassay (RIA) was more sensitive for MOG autoantibody detection than other methodologies, including monomer-based RIA, ELISA or fluorescent-activated cell sorting (FACS). Autoantibodies from individuals with acute disseminated encephalomyelitis (ADEM) selectively bound the folded MOG tetramer, whereas sera from mice with experimental autoimmune encephalomyelitis induced with MOG peptide immunoprecipitated only the unfolded tetramer. MOG-specific autoantibodies were identified in a subset of ADEM but only rarely in adult-onset MS cases, indicating that MOG is a more prominent target antigen in ADEM than MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237795      PMCID: PMC3429369          DOI: 10.1038/nm1488

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  30 in total

1.  Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.

Authors:  M Reindl; C Linington; U Brehm; R Egg; E Dilitz; F Deisenhammer; W Poewe; T Berger
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

2.  Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination.

Authors:  Hans-Christian von Büdingen; Stephen L Hauser; Jean-Christophe Ouallet; Naoyuki Tanuma; Til Menge; Claude P Genain
Journal:  Eur J Immunol       Date:  2004-08       Impact factor: 5.532

3.  Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.

Authors:  Thomas Berger; Paul Rubner; Franz Schautzer; Robert Egg; Hanno Ulmer; Irmgard Mayringer; Erika Dilitz; Florian Deisenhammer; Markus Reindl
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

4.  Acute disseminated encephalomyelitis in children: clinical features and HLA-DR linkage.

Authors:  Zh R Idrissova; M N Boldyreva; E P Dekonenko; N A Malishev; I Y Leontyeva; I N Martinenko; A S Petrukhin
Journal:  Eur J Neurol       Date:  2003-09       Impact factor: 6.089

5.  Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.

Authors:  V Lampasona; D Franciotta; R Furlan; S Zanaboni; R Fazio; E Bonifacio; G Comi; G Martino
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

6.  Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.

Authors:  Patrice H Lalive; Til Menge; Cecile Delarasse; Bruno Della Gaspera; Danielle Pham-Dinh; Pablo Villoslada; H-C von Büdingen; Claude P Genain
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

7.  The organizing principle in the formation of the T cell receptor-CD3 complex.

Authors:  Matthew E Call; Jason Pyrdol; Martin Wiedmann; Kai W Wucherpfennig
Journal:  Cell       Date:  2002-12-27       Impact factor: 41.582

8.  High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia.

Authors:  L Fossati-Jimack; L Reininger; Y Chicheportiche; R Clynes; J V Ravetch; T Honjo; S Izui
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

9.  Commentary: Sorting the wheat from the chaff: identifying demyelinating components of the myelin oligodendrocyte glycoprotein (MOG)-specific autoantibody repertoire.

Authors:  Emily Mathey; Constanze Breithaupt; Anna S Schubart; Christopher Linington
Journal:  Eur J Immunol       Date:  2004-08       Impact factor: 5.532

Review 10.  Postinfectious encephalomyelitis.

Authors:  Dean M Wingerchuk
Journal:  Curr Neurol Neurosci Rep       Date:  2003-05       Impact factor: 6.030

View more
  119 in total

Review 1.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

Review 2.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

3.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

4.  Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future.

Authors:  Philip L De Jager
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

Review 5.  Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays.

Authors:  Edwin Liu; George S Eisenbarth
Journal:  Clin Immunol       Date:  2007-09-27       Impact factor: 3.969

Review 6.  Pediatric multiple sclerosis.

Authors:  E Ann Yeh; Tanuja Chitnis; Lauren Krupp; Jayne Ness; Dorothée Chabas; Nancy Kuntz; Emmanuelle Waubant
Journal:  Nat Rev Neurol       Date:  2009-10-13       Impact factor: 42.937

Review 7.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

8.  Pathologic heterogeneity persists in early active multiple sclerosis lesions.

Authors:  Imke Metz; Stephen D Weigand; Bogdan F G Popescu; Josa M Frischer; Joseph E Parisi; Yong Guo; Hans Lassmann; Wolfgang Brück; Claudia F Lucchinetti
Journal:  Ann Neurol       Date:  2014-05-13       Impact factor: 10.422

9.  Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis.

Authors:  Keith Van Haren; Beren H Tomooka; Brian A Kidd; Brenda Banwell; Amit Bar-Or; Tanuja Chitnis; Silvia N Tenembaum; Daniela Pohl; Kevin Rostasy; Russell C Dale; Kevin C O'Connor; David A Hafler; Lawrence Steinman; William H Robinson
Journal:  Mult Scler       Date:  2013-04-23       Impact factor: 6.312

Review 10.  [Rituximab in treatment for neuroimmunological diseases].

Authors:  A Schröder; G Ellrichmann; G Chehab; M Schneider; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.